FDA Approves Yuviwel (Navepegritide) for Achondroplasia in Children 2 Years and Older

The FDA has approved Yuviwel (navepegritide) to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. The approval, dated February 27, 2026, is listed on the FDA Novel Drug Approvals for 2026 page, and the FDA approval package for the application documents the decision.

Navepegritide is a prodrug of C-type natriuretic peptide, or CNP. Achondroplasia is the condition named in the labeled indication, and the approval covers the specific pediatric population the FDA label states, reported here only as a regulatory fact.

The pathway matters for how this approval should be read. The FDA granted the approval under the accelerated approval pathway, under which continued approval may depend on confirmatory evidence. Growth results considered under that pathway should not be presented as proven long-term clinical benefit.

As with every FDA approval, the decision applies to the specific product, Yuviwel, and the specific indication on its label. It does not extend to compounded formulations, research compounds, or any other use of the molecule.